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Introduction: Ventilator-associated pneumonia (VAP) is the most commonly acquired infection in intensive care
units (ICU). Its outcome is related, at least in part, to the host’s response. Statins have anti-inflammatory effects and
may thus improve the outcome. We aimed to assess the impact of prior statin use in the setting of VAP.
Methods: A six-year cohort study was conducted in a French ICU at a teaching hospital. All of the patients with
suspected VAP were included. Baseline characteristics, outcomes, statin exposure, and the description of suspected
episodes were collected prospectively. The primary endpoint was 30-day mortality. Patients who were taking statins
before admission to the ICU whether or not treatment was continued thereafter (‘previous users’ group) were
compared to those without prior statin therapy (‘statin-naive’ group). A survival analysis using a Cox model was
conducted in the whole cohort and in the subgroup of prior statin users.
Results: Among the 349 patients included, 93 (26.6%) had taken statins. At baseline, these patients were at higher
risk of complications than statin-naive ones (for example, older, more likely to be men and to have underlying
diseases, greater simplified acute physiology score II (SAPS II)). There was, however, no difference regarding severity at
the time VAP was suspected (sequential organ failure assessment (SOFA): 9.0 (4.0 to 16.0) versus 8.0 (4.0 to 17.0); P = 0.11).
Nonetheless, 30-day mortality in statin users was not different from that in statin-naive patients (35.5% versus 26.2%,
respectively; adjusted hazard ratio (HR) = 1.23 (0.79 to 1.90) 95% confidence interval (CI); P = 0.36). In contrast, after
limiting analysis to prior statin users and adjusting for potential confounders, those who continued the treatment
had better survival than those who did not (HR = 0.47; (0.22 to 0.97) 95% CI; P = 0.04).
Conclusions: Statin continuation in prior users could provide protective effects in patients with suspected VAP.Introduction
Ventilator-associated pneumonia (VAP) occurs in almost
30% of patients on prolonged mechanical ventilation
(MV) [1]. It is therefore the most common nosocomial
infection in mechanically ventilated patients and is asso-
ciated with high morbidity and mortality despite appro-
priate initial antibiotics [2]. Since MV could promote lung
inflammation (that is, biotrauma) leading to ventilator-
induced lung injury (VILI), especially if applied on infected
lungs, drugs with anti-inflammatory properties are of po-
tential interest in the setting of VAP [3,4]. Moreover, it has* Correspondence: pierre-emmanuel.charles@chu-dijon.fr
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unless otherwise stated.been shown that the outcome of patients with VAP was
closely related, at least in part, to the degree of both pul-
monary and systemic inflammation [5,6].
Statins are lipid-lowering agents that reduce the risk of
cardiovascular events by inhibiting 3-hydroxy-3 methyl-
glutaryl coenzyme A reductase [7,8]. Immunomodulatory
properties have also been described [9]. Although contro-
versial, a number of publications have raised the possibility
that these drugs could exert protective anti-inflammatory
effects in the context of sepsis, especially pneumonia
[10-15]. Interestingly, some experimental studies have
demonstrated a lung-protective effect through VILI at-
tenuation [16,17]. However, it is worth noting that the
clinical relevance of these findings has not been yet dem-
onstrated [18-20]. The main drawback of the studiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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against sepsis was evaluated, is their retrospective design,
which makes it difficult to control for the many clinically
relevant and especially ‘protective’ confounders (that
is, better health follow-up, greater degree of treatment
compliance), since patients with prior statin therapy were
always compared with those without. In addition, since
sepsis was generally community-acquired in these stud-
ies, some significant covariates such as treatment with
antibiotics prior to hospital admission may not have been
reliably recorded. Moreover, both the type and severity of
the infection varied considerably making the case mix
somewhat different from one report to another.
In contrast, interesting results were obtained in certain
randomized controlled trials (RCTs) that targeted one
type of infection and/or one population of patients (for
example, intensive care unit (ICU) patients) [20,21]. Thus,
Makris et al. showed that prior treatment with statins
could decrease mortality and ICU length of stay in selected
patients with VAP. In contrast, a recent RCT that com-
pared atorvastatin to placebo in patients with suspected
VAP has failed to demonstrate any benefit [22].
As a result, statins clinical interest in patients with
VAP is uncertain. Moreover, whether statins should be
stopped or continued in ICU patients remains an un-
solved issue. Since VAP occurs a certain time after ICU
admission in therefore closely followed patients, relevant
data related to episodes of pneumonia can be considered
reliable if collected prospectively, as was the case in our
medical ICU [23]. We therefore decided to assess the
impact of prior statin therapy on the outcome (that is,
ICU all-cause 30-day mortality) of patients with suspected
VAP included in our cohort. To this purpose, two distinct
sets of analysis were performed. First, we compared the
patients with prior statin exposure to those without. Sec-
ond, we considered only the patients with prior exposure
and evaluated mortality according to continuation or dis-
continuation of the drug in the ICU.
Materials and methods
Study population
The database used in this study has already been de-
scribed elsewhere [23]. Briefly, every patient admitted to
our ICU between January, 2006 and January, 2013 was
considered if subjected to MV for more than 48 hours.
Each patient with suspected VAP according to the physi-
cian’s clinical judgment was eligible. However, only
those with a ‘modified’ clinical pulmonary infection score
(CPIS) of five or greater, provided empirical antibiotics
were delivered promptly (that is, day 1), were kept for
analysis in the present work, as in the recently published
‘STATIN-VAP’ study, in order to include the patients
with a sufficiently high level of suspicion regarding VAP
diagnosis [22,24,25].In accordance with French law, no informed consent
was required since all measurements were part of rou-
tine management, as confirmed by our local ethics com-
mittee (Comité de Protection des Personnes Nord-Est),
which gave us its approval for conducting our study.
Definitions
The patients with suspected VAP were classified into
two distinct groups according to prior statin therapy.
Thus, the ‘previous users’ group included all of the pa-
tients treated with statins prior to ICU admission whether
or not they were continued thereafter. The ‘statin-naive’
group included patients without prior statins. For second-
ary analyses (see below), statin previous users were sepa-
rated into two groups according to drug continuation
until VAP episode (that is, statin continuation or discon-
tinuation in the ICU).
Since tracheal aspirate quantitative cultures were per-
formed, the 106 colony-forming units (CFU)/mL cutoff
value was applied for differentiating between positive
and negative results.
Bacteria were considered multidrug resistant (MDR) in
the following cases according to recent recommenda-
tions: (i) Pseudomonas aeruginosa resistant to imipenem
and/or antipseudomonal penicillins and/or one aminoside
and/or ciprofloxacine; (ii) Enterobacteriacae if resistant
to third-generation cephalosporins and/or fluoroquinolone
and/or an aminoside; (iii) Staphylococcus aureus if resistant
to oxacillin [26]. Patients with negative tracheal aspirate
cultures were considered free of MDR bacteria.
Immunosuppression was defined as neutropenia (poly-
morphonuclear cells counts less than 1500/mm3), any
immunosuppressive treatment prior to ICU admission
including steroids if given for more than one month.
Data collection
Using a recording form, ‘modified’ CPIS value, demo-
graphic data and usually reported risk factors for MDR
bacteria were prospectively recorded (that is, time
between VAP suspicion and ICU admission, previous
hospitalization, exposure to antibiotics defined as the
administration of at least one two-day course of antibiotics
within the past 30 days, residence in a nursing home,
underlying chronic obstructive pulmonary disease). The
clinical course of VAP was also assessed through day-1
and day-3 sequential organ failure assessment (SOFA)
scores, the duration of mechanical ventilation and the
number of ventilator-free days. The primary outcome was
30-day all-cause mortality.
Prior statin therapy was assessed through retrospect-
ively collected data after the prospective cohort had been
established. All the available records (both in and out of
hospital) were used to determine whether patients had
received statins before and after ICU admission. They
Figure 1 Flow chart of selection of study patients. ATB, antibiotics; CPIS, clinical pulmonary infection score; ICU, intensive care unit; VAP,
ventilator-associated pneumonia.
Table 1 Patients with suspected VAP
Overall Statin previous users Statin-naive patients P
(n = 349) (n = 93) (n = 256)
Age (years) 64.0 (17.0-94.0) 68.0 (27.0-90.0) 63.0 (17.0-94.0) <0.01
SAPS II 50.0 (6.0-109.0) 54.0 (18.0-109.0) 49.0 (6.0-99.0)) 0.06
Gender, male (n (%)) 254 (72.8) 80 (86.0) 174 (68.0) <0.01
Hospitalization prior to ICU admission (n (%)) 347 (62.3) 89 (67.9) 258 (60.6) 0.14
Underlying disease(s)
COPD (n (%)) 99 (17.7) 33 (25.1) 66 (15.5) 0.01
Chronic renal failure (n (%)) 23 (6.6) 10 (10.9) 13 (5.1) 0.05
Chronic cardiac disease (n (%)) 138 (39.6) 65 (70.6) 73 (28.5) <0.01
Diabetes mellitus (n (%)) 67 (19.2) 29 (31.5) 38 (14.8) <0.01
Cirrhosis (n (%)) 17 (4.9) 2 (2.2) 15 (5.9) 0.16
Immunosuppression (excepting steroids) (n (%)) 17 (4.9) 4 (4.3) 13 (5.1) 0.78
Steroids (n (%)) 20 (5.8) 8 (8.7) 12 (4.7) 0.16
Cancer (n (%)) 31 (8.9) 10 (10.9) 21 (8.2) 0.44
Nursing-home resident (n (%)) 16 (4.6) 2 (2.1) 14 (5.5) 0.19
Main admission diagnosis 0.20
Respiratory distress (n (%)) 133 (38.1) 33 (35.5) 100 (39.1) 0.54
Extrapulmonary sepsis (n (%)) 107 (30.6) 33 (35.5) 74 (69.2) 0.24
Neurologic failure (n (%)) 50 (14.3) 10 (10.7) 40 (15.6) 0.24
Abdominal surgery (n (%)) 17 (4.9) 2 (2.1) 15 (5.8) 0.15
Miscellaneous (n (%)) 42 (12.0) 15 (16.1) 27 (10.5) 0.16
Baseline characteristics according to statin exposure. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit;
COPD, chronic obstructive pulmonary disease; MV, mechanical ventilation.
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statins prior to ICU admission regardless of how long
they did.
In addition, procalcitonin (PCT) measurement was
usually performed in every patient with suspected sepsis
as a reliable tool to improve diagnosis and antimicrobial
management [27]. Tracheal aspirate samples were taken
in every patient within a 24-hour period following the
clinical suspicion. The results of the bacterial cultures
were used to calculate the ‘day-3 CPIS’ since one point
was added to the value obtained at day 1 if at least
106 CFU /mL were recovered. One point was then added
if the direct examination showed the same germ.
VAP management
The guidelines for the antibiotic therapy management
were based on the knowledge of local susceptibility pat-
terns of the most frequently isolated bacteria, as well on
the clinical judgment of the attending physician. The
first-line treatment (that is, the one delivered within the
first 24 hours following the clinical suspicion of VAP)
was considered appropriate if the isolated pathogen(s)
was (were) susceptible to at least one drug administeredTable 2 Suspected VAP episode description according to stat
Overall
(n = 349)
Time elapsed between ICU admission and VAP (days) 10.0 (2.0-157.0)
Time elapsed between MV onset and VAP (days) 10.0 (2.0-156.0)
Early VAP (n (%)) 108 (30.9)
Septic shock (n (%)) 117 (33.6)
Appropriate antibiotic therapy (n (%)) 262 (76.4)
Concurrent therapy during VAP period
Steroids (n (%)) 153 (45.0)
RRT (n (%)) 83 (24.4)
CPIS D1 6.0 (2.0-11.0)
CPIS D3 7.0 (5.0-13.0)
SOFA D1 8.0 (4.0-17.01)
SOFA D3 8.0 (4.0-18.0)
PCT D-1 1.2 (0.1-172.0)
PCT D1 1.2 (0.1-91.4)
PCT D2 1.5 (0.1-162.0)
PCT D3 1.3 (0.1-345.2)
PCT D4 1.2 (0.1-199.2)
Ventilator-free days 4.0 (0.0-112.0)
Length of ICU stay (days) 26.0 (4.0-204.0)
Duration of MV (days) 20.0 (2.0-176.0)
30-day mortality (n (%)) 100 (28.6)
VAP, ventilator-associated pneumonia; ICU, intensive care unit; MV, mechanical ven
D, day; SOFA, sequential organ failure assessment; PCT, procalcitonin.at the onset of sepsis according to the corresponding
susceptibility testing report. When no antibiotic was
given within the first 24 hours of management, the treat-
ment was considered inappropriate regardless of the
subsequently isolated pathogen.
Statistical analysis
Values are expressed as median (range) unless otherwise
stated.
Comparative analysis
First, patients with VAP were compared according to
prior statin use as defined above. Continuous variables
were compared using the Mann-Whitney U test, and cat-
egorical variables were compared using the chi-squared
test.
Survival analysis
Then, 30-day survival analyses were conducted.
First, the whole cohort was considered. The survival of
patients regarding statin therapy was analyzed through
the construction of the corresponding Kaplan-Meier
curves compared by the log-rank test. Then, in addition toin exposure and outcome
Statin previous users Statin-naive patients P
(n = 93) (n = 256)
10.0 (2.0-72.0) 10.0 (2.0-157.0) 0.62
10.0 (2.0-69.0) 10.0 (2.0-156.0) 0.48
27 (29.0) 81 (31.6) 0.64
35 (38.0) 82 (32.0) 0.29
70 (76.9) 192 (76.2) 0.89
41 (45.1) 112 (45.0) 0.99
29 (31.9) 54 (21.7) 0.05
5.0 (2.0-9.0) 6.0 (2.0-11.0) 0.32
7.0 (5.0-11.0) 7.0 (5.0-13.0) 0.25
9.0 (4.0-16.0) 8.0 (4.0-17.0) 0.11
8.0 (4.0-15.0) 8.0 (4.0-18.0) 0.63
1.1 (0.1-55.9) 1.4 (0.1-172.0) 0.42
1.3 (0.1-30.0) 1.2 (0.1-91.4) 0.41
1.4 (0.1-64.3) 1.6 (0.1-162.0) 0.28
1.5 (0.1-56.2) 1.2 (0.1-345.2) 0.71
1.0 (0.1-35.3) 1.2 (0.1-199.2) 0.61
2.0 (0.0-30.0) 4.0 (0.0-112.0) <0.01
25.0 (4.0-147.0) 26.0 (5.0-204.0) 0.80
20.0 (2.0-121.0) 19.0 (2.0-176.0) 0.42
33 (35.5) 67 (26.2) 0.09
tilation; RRT, renal replacement therapy; CPIS, clinical pulmonary infection score;
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every variable associated with 30-day death in the ICU ac-
cording to the univariate analysis was entered into a multi-
variate Cox model if the P value was less than 0.20.
In the second set of analyses restricted to prior statin
users, 30-day survival was evaluated by univariate analysis
as described above. Again, the corresponding Kaplan-
Meier curve was constructed and a multivariate analysis
based on a Cox model was performed in an attempt to
withdraw potential confounders. In addition to statin use
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Length of ICU stay until VAP (days)
Duration of MV until VAP (days)
Septic shock (VAP day 1) (n (%))
Late-onset VAP (≥5 days after MV onset) (n (%))
MDR bacteria (n (%))
Appropriate antibiotic therapy within the first 24 hours of VAP (n (%))
Steroids during VAP period (n (%))
Statin exposure prior to ICU admission (n (%))
Statin continuation after ICU admission (n (%))
VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II;
score; SOFA, sequential organ failure assessment; ICU, intensive care unit; MV, mech‘statin discontinued’), covariates were selected according to
the results of the univariate analysis. Only those associated
with death with a P value less than 0.20 were included into
the model.
For all Cox model analyses, scaled Schoenfeld residuals
(graphical inspection and formal testing for a nonzero
slope in a regression of the residuals on functions of time)
were used to check the Cox model, for each variable.
The functional form of continuous variables (V1, V2…)
was checked with martingale residual analysis and by
means of fractional polynomials.escription of the study patients according to the
Survivors Nonsurvivors P
(n = 249) (n = 100)
62.0 (17.0-94.0) 68.5 (32.0-90.0) <0.01
47.0 (6.0-109.0) 55.0 (15.0-99.0) <0.01
182 (73.1) 72 (72.0) 0.83
12 (4.8) 11 (11.0) 0.04
84 (33.9) 54 (54.0) <0.01
45 (18.1) 22 (22.0) 0.41
45 (18.1) 21 (21.0) 0.53
6 (2.4) 11 (11.0) <0.01
9 (3.6) 8 (8.0) 0.09
25 (10.1) 6 (6.0) 0.21
16 (6.4) 0 (0.0) <0.01
0.02
101 (40.6) 32 (32.0) 0.13
64 (25.7) 43 (43.0) <0.01
40 (16.1) 10 (10.0) 0.14
14 (5.6) 3 (3.0) 0.30
30 (12.0) 12 (12.0) 0.99
6.0 (2.0-11.0) 5.0 (3.0-9.0) 0.06
7.0 (5.0-13.0) 7.0 (5.0-11.0) 0.20
7.0 (4.0-17.0) 10.0 (4.0-16.0) <0.01
7.0 (4.0-16.0) 9.0 (4.0-18.0) <0.01
10.0 (2.0-157.0) 11.0 (2.0-72.0) 0.48
10.0 (2.0-156.0) 10.0 (2.0-70.0) 0.37
71 (28.6) 46 (46.0) <0.01
166 (66.7) 75 (75.0) 0.13
76 (30.8) 41 (41.0) 0.05
193 (78.4) 69 (69.0) 0.16
89 (36.8) 64 (64.0) <0.01
60 (24.1) 33 (33.0) 0.09
37 (14.8) 15 (15.0) 0.97
COPD, chronic obstructive pulmonary disease; CPIS, clinical pulmonary infection


















Time elapsed since VAP onset (days)
Figure 2 Survival analysis of patients with suspected VAP
according to the prior use of statin. Red-line: ‘statin previous
users’; blue-line: ‘statin-naive patients’ (log-rank test: P = 0.04). VAP,
ventilator-associated pneumonia.
Table 4 Independent predictors of 30-day mortality in
patients with suspected VAP
Hazard ratio 95% CI P
Steroids during VAP 1.93 1.25-2.98 <0.01
Cirrhosis 3.72 1.83-4.31 <0.01
Age 1.02 1.01-1.04 <0.01
SAPS II 1.02 1.01-1.04 <0.01
SOFA day 1 1.15 1.07-1.23 <0.01
Statin prior exposure 1.23 0.79-1.90 0.36
VAP, ventilator-associated pneumonia; CI, confidence interval; SAPS II, simplified
acute physiology score II; SOFA, sequential organ failure assessment.
Bruyere et al. Critical Care 2014, 18:R83 Page 6 of 11
http://ccforum.com/content/18/2/R83No a priori interactions were clinically indicated or
tested.
The goodness-of-fit was assessed by the Cox-Snell re-
siduals, bias-corrected Akaike’s information criterion.
All tests were two-tailed. A P value of <0.05 was con-
sidered statistically significant. STATA software was used
for all analyses (StataCorp, College Station, TX, USA).
Results
Patients’ characteristics
Between 1 January 2006 and 31 January 2013, 631 epi-
sodes of suspected VAP were recorded. Seventy-four epi-
sodes were excluded because of missing data (n = 22),
inclusion in a RCT comparing atorvastatin to placebo
for the management of VAP (n = 52), CPIS less than five
or the absence of antibiotics delivered on day 1 (n = 208).
Among the 349 remaining cases, 93 (26.6%) had been
treated with statins, while 256 had not (73.4%) (Figure 1).
Among the former patients (that is, ‘previous users’), statins
were continued until VAP in 52 (55.9%) for a duration of
9.2 (2.0 to 71.0) days.
The main baseline characteristics of the included pa-
tients are presented in Table 1. It is worth noting that
statin previous users were sicker than statin-naive patients
at ICU admission. Actually, the statin patients were signifi-
cantly older, had higher SAPS II scores on admission, and
were more likely to harbor underlying diseases. In contrast,
main admission diagnosis was similar.
VAP episodes description
Among the 349 episodes of VAP analyzed, a positive bac-
terial culture was obtained in around 80% of the cases in
each group. For the whole population, Enterobacteriaceae
were the most frequently isolated pathogen (29.9%). This
proportion reached 33.5% in the patients with statins.
Overall, MDR germs, as defined above, were isolated
in 33.1% of patients with statins and 28.6% of those
without (P = 0.33).
The first-line antibiotic therapy was appropriate in most
of the cases (76.9% and 76.2% in the ‘statin previous users’
and in the ‘statin-naive’ groups, respectively; P = 0.89).
Regarding the severity of VAP episodes, the occurrence
of septic shock on day 1 was similar in the two groups
(38.0% versus 32.0%, P = 0.29), as were the CPIS values and
the SOFA scores on day 1 and day 3 (Table 2). Similarly,
the same proportions of patients in both groups were
given steroids (45.1% vs. 45.0%, respectively; P = 0.99).
No significant difference was found regarding PCT
measurements.
Survival analysis
The overall mortality rate for the whole cohort reached
28.6%. Prior statin therapy did not modify the outcome
(Tables 2 and 3) (Figure 2).To eliminate potential confounders, a time-dependent
multivariate analysis based on a Cox model was conducted.
Statin therapy was found not to have any protective effect
(Table 4). Conversely, as expected, immunosuppression,
age, cirrhosis, high SAPS II, SOFA day-1 values and the
use of steroids during the VAP episode were independently
associated with decreased survival in the ICU.
We conducted additional survival analyses within the
subset of patients in whom statins previous users (n = 93).
The patients in whom statins were continued once admit-
ted to the ICU (n = 52) were distinguished from the
remaining ones (n = 41).
First, we compared those patients with respect to their
baseline characteristics and main admission diagnosis as
well in an attempt to identify potential factors likely to
have influence on the decision to stop statin therapy in
the ICU (Table 5). No difference was found between
groups, except hospitalization prior to ICU admission
that was found to be more frequent in the patients in
whom statins were discontinued.
The mortality rate tended to be lower in patients who
continued statin therapy than in the others (28.8% vs.
Table 5 Patients with suspected VAP and previous exposure to statins
Statin continuation Statin discontinuation P
(n = 52) (n = 41)
Age (years) 67.5 (27.0-85.0) 68.0 (46.0-90.0) 0.99
SAPS II 51.0 (18.0-109.0) 55.0 (24.0-91.0) 0.56
Gender, male (n (%)) 44 (84.6) 36 (87.8) 0.66
Hospitalization prior to ICU admission (n (%)) 31 (59.6) 33 (80.5) 0.03
Underlying disease(s)
COPD (n (%)) 10 (19.2) 14 (34.1) 0.10
Chronic renal failure (n (%)) 6 (11.8) 4 (9.7) 0.76
Chronic cardiac disease (n (%)) 37 (72.5) 28 (68.3) 0.66
Diabetes mellitus (n (%)) 20 (39.2) 9 (21.9) 0.07
Cirrhosis (n (%)) 0 (0.0) 2 (4.9) 0.11
Immunosuppression (excepting steroids) (n (%)) 2 (4.9) 2 (3.9) 0.82
Steroids (n (%)) 5 (9.8) 3 (7.3) 0.67
Cancer (n (%)) 6 (11.8) 4 (9.8) 0.76
Nursing-home resident (n (%)) 1 (1.9) 1 (2.4) 0.86
Main admission diagnosis 0.20
Respiratory distress (n (%)) 22 (42.3) 11 (26.8) 0.12
Extrapulmonary sepsis (n (%)) 15 (28.8) 18 (43.9) 0.13
Neurologic failure (n (%)) 4 (7.7) 6 (14.6) 0.28
Abdominal surgery (n (%)) 0 (0.0) 2 (4.9) 0.11
Miscellaneous (n (%)) 11 (21.1) 4 (9.8) 0.14
Renal failure on admission (Yes (%)) 29 (55.8) 21 (51.2) 0.66
Nasogastric tube (Yes (%)) 52 (100) 39 (95.1) 0.11
Baseline characteristics according to statin continuation. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit;
COPD, chronic obstructive pulmonary disease.
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age and SOFA day-1 values, statin continuation in prior
users was found to be significantly associated with an
improved outcome (adjusted hazard ratio (HR) = 0.47;
(0.22 to 0.97) 95% confidence interval (CI); P = 0.04)
(Table 7) (Figure 3). Similar findings were obtained when
the analysis was restricted to the only patients with posi-
tive quantitative cultures (n = 73), that is those with con-
firmed VAP (Table 8).
Discussion
In addition to their lipid-lowering properties, statins have
pleiotropic effects, which are likely to improve the out-
come of patients with coronary heart disease by reducing
the risk of new cardiovascular events. Among these ef-
fects, statins are able to modulate the host immune re-
sponse [9]. This probably results from a wide range of
interferences with proinflammatory pathways. Using statin
therapy to protect patients with sepsis could therefore be
a reasonable strategy, as these drugs could dampen an
overwhelming host inflammatory response to infection,
especially within the lung [28]. Many studies, mainlyobservational, have addressed this issue [15]. However,
contrasting findings have been reported. This may result
from both study design and the widely varying characteris-
tics of the populations included. All in all, the protective
effect of statins during sepsis remains an unsolved issue.
Ventilator-associated pneumonia remains one of the
major complications of protracted stays in the ICU. Des-
pite early and appropriate antibiotics, the response rates
to antibacterial therapy remain low. This could result
from deep alterations of the host immune response in
this setting, as a shift toward a proinflammatory state
occurs within the lung if subjected to MV. This proin-
flammatory state is likely to weaken the host’s ability to
clear pathogens [29]. As suggested in previous studies
[20], statin therapy may therefore have a beneficial effect
in patients with VAP.
We report herein the findings from a single-center co-
hort study that investigated, retrospectively, the effects of
statin therapy on the outcome of patients with suspected
VAP. In the first set of analyses, we compared statin-naive
patients with those who received statins, whether or not
treatment was discontinued upon admission to the ICU.
Table 6 Baseline characteristics and VAP episode description in the statin previous users according to the 30-day mortality
Survivors Nonsurvivors P
(n = 60) (n = 33)
Age (years) 62.5 (27.0-81.0) 74.0 (50.0-90.0) <0.01
SAPS II (points) 48.0 (18.0-109.0) 57.0 (30.0-86.0) 0.01
Gender, male (n (%)) 50 (83.3) 30 (90.9) 0.31
Hospitalization prior to ICU admission (n (%)) 41 (68.3) 23 (69.7) 0.89
Underlying disease(s) (n (%))
Chronic renal failure 5 (8.5) 5 (15.1) 0.32
Cardiac chronic disease 38 (64.4) 27 (81.8) 0.08
Diabetes mellitus 19 (32.2) 10 (30.3) 0.99
COPD 15 (25.0) 9 (27.3) 0.81
Cirrhosis 1 (1.7) 1 (3.3) 0.67
Immunosuppression 4 (6.8) 0 (0.0) 0.13
Cancer 7 (11.9) 3 (9.1) 0.68
Nursing-home resident (n (%)) 2 (3.3) 0 (0.0) 0.29
Main admission diagnosis
Respiratory distress (n (%)) 21 (35.0) 12 (36.3) 0.89
Extrapulmonary sepsis (n (%)) 19 (31.7) 14 (42.4) 0.30
Neurologic failure (n (%)) 6 (10.0) 4 (12.1) 0.75
Abdominal surgery (n (%)) 2 (3.3) 0 (0.0) 0.29
Miscellaneous (n (%)) 12 (20.0) 3 (9.1) 0.17
Nasogastric tube (Yes (%)) 58 (96.7) 33 (100) 0.30
CPIS day-1 5.0 (2.0-9.0) 5.0 (3.0-8.0) 0.38
CPIS day-3 7.0 (5.0-11.0) 7.0 (5.0-10.0) 0.30
SOFA day-1 7.0 (4.0-15.0) 10.0 (5.0-16.0) <0.01
SOFA day-3 7.0 (4.0-14.0) 8.0 (4.0-15.0) 0.08
Renal failure on admission (Yes (%)) 30 (50.0) 20 (60.6) 0.33
Serum creatinine (VAP day-1) 90.0 (27.0-404.0) 137.0 (34.0-321.0) 0.02
Serum creatinine (VAP day-3) 84.0 (14.0-332.0) 111.0 (27.0-329.0) 0.20
Length of ICU stay until VAP (days) 10.0 (2.0-60.0) 10.0 (2.0-72.0) 0.90
Duration of MV until VAP (days) 12.0 (2.0-52.0) 7.0 (2.0-69.0) 0.44
Septic shock (VAP day-1) (n (%)) 18 (30.5) 17 (51.5) 0.05
Late-onset VAP (≥5 days after MV onset) (n (%)) 41 (68.3) 25 (75.8) 0.45
MDR bacteria (n (%)) 19 (32.2) 14 (42.4) 0.33
Appropriate antibiotic therapy within the first 24-hour of VAP (n (%)) 49 (83.0) 21 (65.6) 0.06
Steroids therapy during VAP period (n (%)) 23 (39.6) 18 (54.5) 0.17
Statin continuation after ICU admission (n (%)) 37 (61.7) 15 (45.4) 0.13
VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CPIS,
clinical pulmonary infection score; SOFA, sequential organ failure assessment; MV, mechanical ventilation; MDR, multidrug resistant.
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groups, and this despite the fact that previous users were
older and sicker. A multivariate survival analysis was
then conducted but failed to demonstrate any difference in
survival despite multiple adjustments. Moreover, various
relevant variables may have been missing from our ana-
lysis, especially because of the retrospective design of ourstudy. Thus, additional atherosclerosis risk factors such as
smoking or obesity, which are frequently associated with
statin intake, could act as masking confounders. Unfortu-
nately, we were unable to adjust for such factors, thus mak-
ing it more difficult to demonstrate any beneficial effect.
We therefore conducted a second set of analyses re-
stricted to patients with prior statin therapy, in an
Table 8 Independent predictors of 30-day death in the
statin previous users subset of patients with clinically




Age 1.10 1.04-1.20 <0.01




VAP, ventilator-associated pneumonia; CI, confidence interval; SOFA, sequential
organ failure assessment; ICU, intensive care unit.
Table 7 Independent predictors of 30-day death in the





Age 1.06 1.02-1.11 <0.01




VAP, ventilator-associated pneumonia; CI, confidence interval; SOFA, sequential
organ failure assessment; ICU, intensive care unit.
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supported by the fact that it remains unknown whether
statins should be continued or not when patients on statin
therapy present with a critical illness requiring treatment
in an ICU, notably because of toxicity concerns. Similar to
our first findings, we found no statistically significant dif-
ference between patients who continued statin therapy and
those who did not after admission to the ICU. However,
after adjusting for potential confounders, continued statin
therapy was found to be independently related to survival
in the ICU. Several explanations could be provided. First,
this subset of patients (that is, previous statin users) was
probably more homogeneous regarding cardiovascular
risk factors and associated illnesses, thereby making
the existence of uncontrolled confounding variables less
likely. Second, the protective effect of statins during sep-
sis may decrease with the duration of discontinuation.
Obviously, the most consistent published data were ob-
tained in patients hospitalized with severe community-
acquired pneumonia, that is to say patients actually
exposed to statins at least until the onset of sepsis [13,14].
If statins were discontinued on admission, it is likely that

















Time elapsed since VAP onset (days)
Figure 3 Survival analysis of patients with suspected VAP in
the statin prior users subset according to drug continuation.
Red-line: ‘statin continuation’; blue-line: ‘statin discontinuation’
(log-rank test: P = 0.13). VAP, ventilator-associated pneumonia.not abolished when the VAP occurred, that is to say several
days, if not weeks, later. This is especially true in our co-
hort since most of the VAP episodes recorded were late-
onset. Conversely, a previously published RCT showed
that in previous statin users hospitalized with signs of in-
fection, drug continuation was not associated with a better
outcome [30]. It is worth noting that illness severity was
mild in this study. Indeed, the same authors have reported
more recently the results of another RCT comparing ator-
vastatin 20 mg daily to placebo given upon ICU admission
to critically ill patients with sepsis [21]. These authors
showed that in the predefined subgroup of patients who
received statins prior to ICU admission there was a signifi-
cant decrease in 28-day mortality in the treatment arm
when compared to placebo, whereas no effect was mea-
sured if the new users (that is, statin-naive patients) were
also considered. It is worth noting that in our cohort, we
did not find any statin new users. We cannot therefore
conclude about the putative protective effect of statin de
novo treatment in the ICU, an issue addressed by several
ongoing or recently completed RCTs. Among them, the
‘STATIN VAP’ study showed that no beneficial effect
could be expected from simvastatin when given in patients
with suspected VAP [22]. Although speculative, one can
hypothesize that statin anti-inflammatory effects, if any,
could be obtained and protect the host as well only if
given prior to infection.
Several limitations should, however, be mentioned.
First, although most of the data were collected prospect-
ively, information regarding statin use was acquired retro-
spectively and could therefore be a matter of concern.
However, we systematically excluded from the analysis pa-
tients with unreliable or missing data. Second, because of
the retrospective design of the study, the risk of missing
confounding data is real. Our findings should thus be inter-
preted with caution. Third, the assessment of renal func-
tion was based on serum creatinine alone, which is subject
to criticism, especially in the ICU setting. Fourth, liver test
abnormalities on admission were not recorded in our data-
base. We cannot exclude that statin discontinuation was
thus influenced in some patients, accounting thereby for
differences of outcome. In addition, we were unable to
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patients since, for instance, creatine kinase levels were not
available. Some of our conclusions are therefore only
speculative. Moreover, we did not record which type of
statin was used in the included patients, despite the fact
that anti-inflammatory properties may differ according to
the considered subclass (that is, lipophilic vs. hydrophilic).
Similarly, patients were classified as previous users if any
statin therapy has been given prior to ICU admission re-
gardless of treatment duration, making unlikely any con-
clusion about the minimal required time of exposure. In
addition, inflammation assessment relied on the sole PCT
measurement. Inflammatory cytokines assessment would
have maybe provided different insights regarding host re-
sponse. However, PCT monitoring has been shown to be
clinically relevant in patients with VAP [31]. Moreover, we
cannot exclude that some patients without confirmed
VAP were included in the study since we used diagnosis
criteria known to lack of specificity [24]. As a result, any
possible protective effect of statins in our cohort may be
independent from VAP occurrence. However, since we
considered the only episodes in which the physician in
charge promptly delivered antibiotics, we believe that it re-
flects real-life practice. In addition, the CPIS value on day
3 was rather high (6.5 (2) points within the whole cohort),
strongly suggesting thereby VAP diagnosis in our patients.
Moreover, it is worth noting that such a beneficial effect
on survival of statin exposure was also noticed in the sub-
set of patients of microbiologically proven VAP. Finally,
the sample size in our subgroup analysis was quite small,
raising the risk of a type-2 error because of a lack of statis-
tical power.
Conclusions
In our cohort, continuing statins after admission to an
ICU may have a protective effect in patients with suspected
VAP.
Key messages
 Statins protective effects in patients with pneumonia
as well as drug continuation after ICU admission are
unsolved issues.
 In our cohort of patients with suspected ventilator-
associated pneumonia, statin continuation in previ-
ous users was shown to be an independent predictor
of survival.
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